今天就趁这个机会， 再 给大家盘点几款真正实力强、性价比高的国货之光， 让你用便宜的价 格，也能买到优质的产品： 洞见（DJ00123987）——不一样的观点，不一样的故事，3000万人订阅的微信大号。点击标 题下蓝字"洞见"关注，我们将为您提供有价值、有意思的延伸阅读。 普通孩子想要逆袭？关键在于这一点 预约直播，教你培养孩子思辨力 大家有没有发现最近几年我们的国货在开挂的路上，越走越远！ 高颜值+高性价比+超好用， 怪不得我一看消费记录，接近一半的都是国货单品。 相比于之前"质量堪忧，包装廉价"的刻板印象，短短几年，国货市场已经迅速崛起，一个个品牌 如雨后春笋般冒出来，让人应接不暇。 一些新锐国货： 诗朗、片仔癀、马应龙 等，也一直在用专业实力征服国人。 国货崛起，让 中国制造 这四个大字也有了更特别的意义。 这些是我们经过长时间的 试用、测评 ， 社群读者好评 反馈后，选出的 使用体验好 、 价格 良心 、 效果出众 的"优质国货"。 请大家耐心的看完本文，您的认可是对"国货崛起"贡献的一份力量。 洞见 x 品质国货 点击下图 立即购买↓ 1、 新升级 诗朗洗发水， 防脱固发 ， 69元2瓶 2、 荣晟 ...

Core Insights - The toothpaste packaging industry is experiencing rapid growth due to increasing awareness of oral health, with the market size in China projected to reach 358.50 billion yuan in 2024, a year-on-year increase of 3.6% [1][7]. - By 2025, the market size is expected to grow to approximately 370.83 billion yuan, driven by rising consumer demands for product quality and packaging design [1][7]. Industry Overview - Toothpaste packaging serves multiple functions, including product protection, user experience enhancement, brand communication, and environmental responsibility [3][7]. - The industry encompasses both inner packaging (directly in contact with toothpaste) and outer packaging (providing protection and brand display) [3][4]. Market Dynamics - The industry is influenced by rising disposable income and consumer spending in China, with per capita disposable income reaching 21,840 yuan in the first half of 2025, a nominal increase of 5.3% year-on-year [5][6]. - The demand for high-quality, eco-friendly, and personalized packaging is expected to drive the industry's transformation towards premium and sustainable solutions [6][10][13]. Competitive Landscape - The toothpaste packaging market is characterized by significant concentration, with major international players like Amcor and Tetra Pak dominating the high-end market [8][9]. - Domestic companies such as Zijiang Group and Kingfa Technology are increasingly replacing imports through technological innovation and product differentiation [9]. Industry Trends - The industry is witnessing a shift towards high-end packaging, with companies using premium materials and innovative designs to enhance product value [10]. - Smart packaging is emerging as a trend, incorporating technology like QR codes for improved consumer engagement and product traceability [11][12]. - Sustainability is becoming a key focus, with brands adopting recyclable and biodegradable materials to meet consumer and regulatory demands [13]. - Personalization is on the rise, with packaging tailored to specific consumer demographics, including children and seniors [14].

Core Insights - The 2025 China-France Brand Week and the 11th China-France Brand Summit were held in Paris, showcasing the importance of international collaboration and brand promotion [1] - Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. was recognized as a representative of the Chinese traditional medicine industry and selected for the "Chinese Brands Worth Recommending to the World" project [1][6] - The summit aimed to explore new paths and opportunities for the internationalization of Chinese brands, gathering high-level representatives from both countries [1] Group 1 - Pien Tze Huang has established itself as a significant symbol of Chinese culture along the Maritime Silk Road, promoting traditional Chinese medicine internationally [3] - The company is actively exploring cross-border e-commerce and localized marketing strategies while obtaining market access in regions like ASEAN and Africa [3] - Pien Tze Huang aims to integrate traditional Chinese medicine with modern health needs through a "medicine + health" model, creating overseas consumption scenarios that combine cultural experience and health services [3] Group 2 - The company has consistently ranked among the top exporters of Chinese patent medicines, with ongoing efforts to establish Pien Tze Huang specialty stores and national medicine halls abroad [4] - As of now, Pien Tze Huang has set up one national medicine hall in Macau and 23 specialty stores in Hong Kong, Macau, and Thailand, with plans for expansion in the US, Canada, Armenia, Singapore, and Malaysia [4] - The company is also collaborating with JD Health and Tongrentang Group to explore overseas sales markets and has obtained multiple registration approvals for its products in Laos, Mozambique, and Hong Kong [4] Group 3 - With the ongoing promotion of projects like "Chinese Brands Worth Recommending to the World," Pien Tze Huang aims to transition from a Chinese brand to a global brand, showcasing the quality of Chinese manufacturing and cultural charm to global consumers [6]

转自：新华财经 2025年9月24日，法国巴黎东方中心内，欧洲先锋选品会拉开帷幕。作为2025中法品牌周核心活动，这场盛会吸引了中欧数百家品牌与采购商参与。漳州片 仔癀药业股份有限公司携经典国药、化妆品、保健食品等全品类产品亮相，以"传统智慧+现代科技"的组合，成为选品会焦点。 开展首日，展台便迎来人流高峰，专业采购商络绎不绝，合作咨询不断。许多采购商对片仔癀将中医智慧与现代消费需求结合的产品理念表现出浓厚兴趣， 现场互动体验区更是排起长队。 为打破文化壁垒，片仔癀采用学术研究与体验营销双管齐下的策略，从科学结论、实验数据等维度出发，以更直观的方式帮助消费者深入了解中医药对个人 健康的益处。同时，通过在选品会现场进行产品介绍和提供试用体验，让更多人接触并认识中医药文化。越来越多的海外消费者愿意体验尝试，始于文化的 吸引力，忠于科学的健康管理。 片仔癀展台成"流量担当" 片仔癀在欧洲先锋选品会的成功，证明中医药不仅是中国的，也是全球的。从塞纳河畔的展台到欧洲消费者的日常健康管理，这片来自漳州的"绿叶"，正通 过产品创新、文化融合与渠道深耕，成长为连接东西方健康理念的桥梁，从中国品牌迈向世界品牌。（张震） 片仔癀 ...

Core Viewpoint - The article discusses the active participation of pharmaceutical companies, particularly Pianzaihuang, in the primary market as limited partners (LPs) in various investment funds, highlighting their strategies to seek new growth opportunities amid fluctuating performance [4][10][12]. Group 1: Pianzaihuang's Investment Activities - Pianzaihuang has committed to invest RMB 200 million as a limited partner in the CICC (Zhangzhou) Medical Industry Investment Partnership, representing 20% of the fund's target size of RMB 1 billion [4][6]. - This marks Pianzaihuang's third investment as an LP since 2025, following previous investments in the "Zhaoying Huikang Fund" and the "Gaoxin Runxin Fund," both with a scale of RMB 1 billion [4][11]. - The company has a strong cash reserve of nearly RMB 5 billion as of June 2025, allowing it to actively engage in investment activities despite recent declines in revenue and profit [12]. Group 2: Fund Details and Partners - The CICC Medical Fund aims to invest in sectors such as traditional Chinese medicine, biomedicine, medical devices, and health services, with a focus on projects related to Pianzaihuang's industry chain [6][8]. - The fund has seven limited partners, with several having connections to Pianzaihuang, indicating a strategic alignment within the investment ecosystem [8]. Group 3: Broader Industry Trends - Other pharmaceutical companies, such as Taige Pharmaceutical and Jiuzhoutong, are also becoming active LPs in the primary market, reflecting a trend among biopharmaceutical firms to diversify their investment portfolios [4][13]. - Companies like Hengrui Medicine and Kanglong Huacheng are also establishing significant investment funds, indicating a robust interest in the primary market driven by strong financial performance [14][16]. - The trend of pharmaceutical companies acting as LPs is seen as a positive signal for the venture capital and private equity landscape, providing much-needed capital to startups and investment firms [17].

2025年金秋，漳州片仔癀药业股份有限公司作为中国中医药"出海"代表企业，以合作品牌身份携全品类产品矩阵重磅登场。继登陆纽约时代广场后，片仔癀再度闪耀埃菲尔铁塔，以东方韵味对 作为片仔癀大健康产业的重要板块之一，片仔癀化妆品此次以两款匠心产品，向世界诠释了东方美学的当代价值，传递出匠心精神与创新力量。 此次巴黎之行，不仅是产品的展示，更是一次文化自信的彰显。在全球化进程中，中国品牌正逐步从"制造出海"迈向"文化出海"，从"价格竞争"转向"价值输出"。片仔癀化妆品作为这一进程的 片仔癀化妆品在2025中法品牌周的亮相，展现出中国品牌在全球价值链中的持续攀升。片仔癀化妆品此次参展的两大产品，分别代表了双重维度：经典传承与当代创新。 45年时光流转，那标志性的"小瓷瓶"早已超越护肤品本身，成为一代代中国人的共同记忆。40多年来，珍珠霜累计销量早已突破1亿瓶，其背后不仅是消费者对产品功效与品质的认可，更是对东 皇后宣娇锦绣礼盒：美学的当代表达 皇后宣娇锦绣礼盒则以现代语言重新诠释美学。景泰蓝背景上的锦绣华服图案，不仅是视觉的盛宴，更是中华服饰文化的凝练表达。礼盒中融汇冬虫夏草提取物、雪莲花提取物、紫芝提取物等中 珍珠 ...

Policy Developments - The National Medical Products Administration (NMPA) has approved industry standards for medical devices utilizing brain-computer interface technology, specifically for closed-loop implantable neurostimulators [1] Drug and Device Approvals - Yipinhong has received a drug registration certificate for oral L-carnitine solution, which is expected to generate approximately 1.257 billion yuan in sales in 2024 within urban and county-level public hospitals in China [2] - Aojing Medical has obtained registration for its absorbable composite bone repair material, enhancing its product lineup in the bone repair sector [3] Capital Market Activities - Pianzaihuang plans to invest 200 million yuan in the CICC (Zhangzhou) Medical Industry Investment Partnership, focusing on sectors such as traditional Chinese medicine, biomedicine, and medical devices [4] - Baiyunshan's subsidiary has signed a share transfer agreement to acquire 11.04% of Nanjing Pharmaceutical for 749 million yuan, aiming to strengthen its strategic cooperation and enhance its competitive advantage in the pharmaceutical distribution business [5] Industry Milestones - The first domestically produced quadrivalent HPV vaccine has been approved for market release, marking a significant advancement in cervical cancer prevention in China [6][7] Public Sentiment Alerts - Duori Pharmaceutical has announced a potential change in control, leading to a temporary suspension of its stock trading [8] - Asia-Pacific Pharmaceutical is also planning a change in control, resulting in a similar stock trading suspension [9]

Group 1 - Rongchang Biopharma's "Taitasip" is proposed for priority review by CDE for treating adult patients with primary IgA nephropathy, showing significant reduction in proteinuria levels [1] - "Taitasip" has already been approved for three indications in China, including myasthenia gravis, rheumatoid arthritis, and systemic lupus erythematosus, with a recent application for Sjögren's syndrome also accepted [1] Group 2 - Baiyunshan and Guangzhou Pharmaceutical Phase II Fund signed a strategic investment agreement to acquire over 144 million shares of Nanjing Pharmaceutical, making it the second-largest shareholder with an 11.04% stake [2] - This strategic investment aims to enhance market competitiveness through resource integration and synergy, potentially impacting Nanjing Pharmaceutical's governance structure and market performance [2] Group 3 - Pian Zai Huang's Chief Financial Officer Yang Haipeng resigned due to work adjustments, with Deputy General Manager He Wei temporarily taking over the CFO duties [3] - The long-term brand value and market position of Pian Zai Huang remain strong, and if the management transition is smooth, the impact on the company's long-term development may be limited [3] Group 4 - Former Chief Technology Officer of Kailai Ying, Hu Xinhui, has joined Hengrui Medicine as Vice President and Chief Technology Officer, indicating a strategic move to strengthen R&D capabilities [4] - Hu Xinhui's appointment is expected to bring new opportunities for Hengrui Medicine's R&D system upgrades, technological breakthroughs, and international development [4] Group 5 - The former Chairman of Guangzhou Pharmaceutical Group, Li Chuyuan, has been reported for violations of discipline and law, leading to his expulsion from the party and public office [5] - This incident highlights governance and internal oversight issues within Guangzhou Pharmaceutical Group, which may affect investor trust and subsequently impact its stock performance and market reputation [5]

证券代码：600436 证券简称：片仔癀 公告编号：2025-032 漳州片仔癀药业股份有限公司关于 公司董事、高级管理人员变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、关于董事、高级管理人员变动的基本情况 漳州片仔癀药业股份有限公司（以下简称"公司"）董事会于近日收到董事、总会计师杨海鹏先生提交的 书面辞职报告。杨海鹏先生因工作调整原因，辞去公司董事及总会计师等职务。辞职后，杨海鹏先生仍 担任顾问职务。具体情况如下： 为确保公司财务管理工作的正常开展，在公司未正式聘任新的总会计师期间，经公司董事会审计委员会 审议，同意指定副总经理何炜先生代行总会计师职责。 特此公告。 漳州片仔癀药业股份有限公司 董 事 会 2025 年 9 月 29 日 证券代码：600436 证券简称：片仔癀 公告编号：2025-034 ■ 二、本事项对公司的影响 根据《中华人民共和国公司法》《漳州片仔癀药业股份有限公司章程》（以下简称"《公司章程》"）等 相关规定，杨海鹏先生的辞职未导致公司董事会成员低于法定人数，不会影响公司董事会正 ...

证券代码：600436 证券简称：片仔癀 公告编号：2025-032 漳州片仔癀药业股份有限公司 关于公司董事、高级管理人员变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、关于董事、高级管理人员变动的基本情况 漳州片仔癀药业股份有限公司（以下简称"公司"）董事会于近日收到董事、总会计师杨海鹏先生提交的 书面辞职报告。杨海鹏先生因工作调整原因，辞去公司董事及总会计师等职务。辞职后，杨海鹏先生仍 担任顾问职务。具体情况如下： ■ 二、本事项对公司的影响 根据《中华人民共和国公司法》《漳州片仔癀药业股份有限公司章程》（以下简称"《公司章程》"）等 相关规定，杨海鹏先生的辞职未导致公司董事会成员低于法定人数，不会影响公司董事会正常运作和日 常经营。杨海鹏先生的辞职报告自送达至公司董事会之日起生效。公司将按照法定程序尽快完成选聘总 会计师的相关工作。 杨海鹏先生在担任公司董事、总会计师期间，恪尽职守、忠诚履职，勤勉尽责、兢兢业业，以良好专业 的素养和创新的理念，有力推动了公司的规范运作、财务管理及健康发展，作出了重要贡献 ...